Forest plot data of the presence of mycobacteria in samples from sarcoidosis patientsversus control samples
| Study | Sarcoidosis n/N | Control n/N | Study weight | Random effects |
| NTM | ||||
| Saboor 31 | 4/20 | 3/22 | 31.94 | 1.58 (0.31–8.15) |
| Popper 36 | 11/35 | 0/39 | 18.26 | 37.08 (2.09–657.9) |
| Li 48 | 14/20 | 0/20 | 17.65 | 91.46 (4.77–1754.5) |
| Klemen 50 | 3/4 | 0/39 | 14.69 | 184.33 (6.26–5425.47) |
| Drake 51 | 4/25 | 0/25 | 17.46 | 10.67 (0.54–209.64) |
| Subtotal | 104 | 145 | 100 | 19.63 (2.74–140.64) |
| Tuberculous and NTM | ||||
| Bocart 28 | 2/22 | 0/22 | 4.20 | 5.49 (0.25–121.18) |
| Gerdes 29 | 0/14 | 0/10 | NE | |
| Mitchell 30 | 5/5 | 0/5 | 2.80 | 121 (2.02–7259.18) |
| Saboor 31 | 14/20 | 5/22 | 9.02 | 7.93 (1.99–31.59) |
| Thakker 32 | 1/14 | 1/11 | 4.59 | 0.77 (0.04–13.87) |
| Fidler 33 | 7/16 | 1/16 | 6.12 | 11.67 (1.23–110.95) |
| Lisby 34 | 0/18 | 0/18 | NE | |
| Ghossein 35 | 0/10 | 0/10 | NE | |
| Richter 38 | 1/24 | 3/57 | 5.95 | 0.78 (0.08–7.93) |
| Cannone 39 | 2/30 | 0/10 | 4.16 | 1.84 (0.08–41.62) |
| Ozcelik 40 | 3/5 | 2/15 | 5.92 | 9.75 (0.95–99.96) |
| Popper 41 | 11/35 | 0/39 | 4.62 | 37.08 (2.09–657.90) |
| Vokurka 42 | 0/15 | 0/27 | NE | |
| Vago 43 | 2/30 | 0/17 | 4.20 | 3.07 (0.14–67.75) |
| Wilsher 44 | 0/31 | 0/10 | NE | |
| Grosser 45 | 35/65 | 1/34 | 6.72 | 38.50 (4.96–298.57) |
| Ishige 47 | 3/15 | 1/15 | 5.75 | 3.50 (0.32–38.23) |
| Li 48 | 16/20 | 0/20 | 4.39 | 150.33 (7.54–2997.83) |
| Klemen 50 | 3/4 | 0/39 | 3.72 | 184.33 (6.26–5425.47) |
| Drake 51 | 15/25 | 0/25 | 4.56 | 75.29 (4.12–1377.06) |
| Eishi 52 | 5/108 | 2/86 | 7.99 | 2.04 (0.39–10.78) |
| Gazouli 53 | 33/46 | 0/20 | 4.62 | 101.74 (5.74–1804.62) |
| Marcoval 56 | 0/35 | 0/39 | NE | |
| Dubaniewicz 57 | 3/50 | 0/10 | 4.31 | 1.55 (0.07–32.27) |
| Fite 58 | 9/23 | 1/23 | 6.35 | 14.14 (1.61–124.11) |
| Subtotal | 680 | 600 | 100 | 9.67 (4.56–20.50) |
Data are presented as % or odds ratio (95% confidence interval), unless otherwise stated. NTM: nontuberculous mycobacteria; NE: not estimable.